Cell Counting Market Research Report Information By Product (Consumables, Instruments) By Application (Research Application, Clinical & Diagnostic Applications, Others) By End-User (Pharmaceutical & Biotechnology Companies, Hospitals, Research Institutes, Others) Forecast till 2032

Global Cell Counting Market Overview

The Cell Counting Market is expected to cross USD 16.91 Billion by 2032 at a CAGR of 7.8% during the forecast period 2023-2032. Cell counting is one of the methods for counting cells in life sciences, including medical diagnosis and treatment. The companies operating in this market acquire both organic and inorganic growth strategies to maintain and develop their positions in the market. The increasing funding for stem cell-based research supports the growth of the market. 

Cell Counting Market Trends

Increasing public-private investments and funding in stem cell-based research impact the growth of the cell counting industry positively. 

Cell counting is one technique for counting cells in the life sciences, such as medical diagnosis and therapy. To preserve and strengthen their positions in the market, the companies that operate in it adopt organic and inorganic growth tactics. The market is expanding thanks to the rising financing for stem cell-based research. The increased need for biologics for treating chronic diseases is one factor driving the market's rise. Managing cell concentration in biologics with spectrophotometers and flow cytometers throughout the development of these products improves the market's growth possibilities. The COVID-19 made a substantial impact on market growth. Based on an individual's genetic profile, personalized medicine seeks to provide personalized treatments.

Furthermore, sophisticated cell-counting devices are becoming increasingly popular among key industry competitors due to their wide range of applications and workflow simplicity. Devices that count cells are essential for assessing patient samples and selecting the best treatment plans. The growing emphasis on customized medicine drives the worldwide need for cell-counting devices. The prevalence of the target diseases, such as diphtheria, HIV, measles, chronic conditions like cancer, additional blood disorders, automated hematology analyzers, and high-throughput flow cytometry are both boosting the market's growth. The market has expanded due to technological advancements in cell counting consumables and equipment that have improved product introductions and adoption.

As a result, it is projected that factors including the increasing prevalence of chronic diseases, advancing technology advancements, and recent product launches within the cell counting industry will fuel the industry's growth. However, the high cost of complicated cell counting machinery and hematological analyzer product recalls may restrain market expansion. The expanding studies and development activities in the biological sciences, biotechnology, and pharmaceuticals drive the demand for cell counting equipment. Various research applications, such as the study of stem cells, drug discovery, and regenerative medicine, depend on these devices, which is driving market expansion. As lymphopenia and eosinopenia were possible COVID-19 indications, the adoption of cell counting instruments significantly increased during the pandemic. More people seek medical care for oral disorders like atrophic glossitis as knowledge of oral health and its connection to general health grows. The demand for treatment alternatives is fueled by the discovery and diagnosis of cases of atrophic glossitis, made possible by advancements in diagnostic methods and the availability of healthcare services.

Market Drivers

• The increasing use of stem cells in various therapeutics is promoting government and private institutes to raise the funding for more development in this area. For instance, in March 2019, the governing Board of the California Institute for Regenerative Medicine (CIRM) funded USD 3.9 million to Ankasa Regenerative Therapeutics to develop the treatment for spinal degeneration which can cause chronic, progressive back pain.

• The growth of the market is driven by the increasing number of product launches in the global cell counting market. Recently, in January 2019 the DeNovix Inc. launched CellDrop Cell Counting without Slides.

• Increased R&D expenditure in the healthcare industry will support the growth of the cell counting market.

• Increasing number of stem cell organizations globally support the growth of the market.

• Rising incidence & prevalence of cancer will support the growth of the market.

Market Restraints

• The high cost of devices and product recalls are likely to hamper the growth of the cell counting market during the forecast period. Recently in May 2019, Beckman Coulter Inc. recalled DxH800 and DxH600 and DxH 900 hematology analyzers due to risk of inaccurate results. 

Cell Counting Market Segment Insights

Cell Counting Product Insights

Cell Counting Application Insights

Cell Counting End-User Insights

Cell Counting Region Insights

Key Players

• Thermo Fisher Scientific (US)


• Merck KGaA (Germany)


• Danaher Corporation (US)


• Bio-Rad Laboratories, Inc. (US)


• Logos Biosystems, Inc. (South Korea)


• Olympus Corporation (Japan)


• Agilent Technologies, Inc. (US)


• PerkinElmer, Inc. (US)


• Sysmex Corporation (Japan)


• Abbott Laboratories (US)